Breaking News, Collaborations & Alliances

NovaSAID, Cadila Enter Drug Development Pact

To pursue new treatments for inflammation and pain

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

NovaSAID AB, a Karolinska Development portfolio company, and Cadila Pharmaceuticals have entered a strategic partnership to develop new treatments for inflammation and pain in conditions such as rheumatoid arthritis. The companies will collaborate on preclinical and clinical development of drug candidates developed by NovaSAID, which will be conducted at Cadila’s facility in Ahmedabad, India.   Cadila will have commercialization rights in India, the Middle East and Africa and the two companies w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters